Cerevel declares positive data from Phase III Parkinson’s treatment trial

Cerevel Therapeutics released positive Phase III TEMPO-3 trial results for tavapadon in Parkinson's disease. Tavapadon, a D1/D5 receptor partial agonist, showed efficacy in a 27-week, double-blind, placebo-controlled study with 507 adult patients aged 40-80 receiving tavapadon as adjunctive therapy to levodopa (LD).

The primary endpoint, change from baseline in total 'on' time without troublesome dyskinesia, was met, with tavapadon patients experiencing a significant 1.1-hour increase compared to LD and placebo. Key secondary endpoints, including reductions in total daily 'off' time and Movement Disorder Society – Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) scores, were also observed.

Tavapadon demonstrated a well-tolerated safety profile, consistent with previous studies, with most adverse events being mild to moderate. The results suggest tavapadon's potential as an effective treatment for Parkinson's disease when used alongside levodopa therapy.